Entasis Therapeutics ETTX Stock
Entasis Therapeutics Price Chart
Entasis Therapeutics ETTX Financial and Trading Overview
Entasis Therapeutics stock price | 2.19 USD |
Previous Close | 2.2 USD |
Open | 2.19 USD |
Bid | 0 USD x 1100 |
Ask | 0 USD x 36900 |
Day's Range | 2.19 - 2.2 USD |
52 Week Range | 1.4 - 3.88 USD |
Volume | 0 USD |
Avg. Volume | 250.76K USD |
Market Cap | 104.33M USD |
Beta (5Y Monthly) | 1.32633 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2 USD |
ETTX Valuation Measures
Enterprise Value | 90.1M USD |
Trailing P/E | N/A |
Forward P/E | -1.5103449 |
PEG Ratio (5 yr expected) | -0.02 |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 1.5346881 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -1.624 |
Trading Information
Entasis Therapeutics Stock Price History
Beta (5Y Monthly) | 1.32633 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 3.88 USD |
52 Week Low | 1.4 USD |
50-Day Moving Average | 2.08 USD |
200-Day Moving Average | 2.17 USD |
ETTX Share Statistics
Avg. Volume (3 month) | 250.76K USD |
Avg. Daily Volume (10-Days) | 86.16K USD |
Shares Outstanding | 47.64M |
Float | 15.99M |
Short Ratio | 0.14 |
% Held by Insiders | 66.34% |
% Held by Institutions | 10.41% |
Shares Short | 72.44K |
Short % of Float | 0.38% |
Short % of Shares Outstanding | 0.14% |
Dividends & Splits
Trailing Annual Dividend Rate | N/A |
Trailing Annual Dividend Yield | N/A |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2021 |
Most Recent Quarter (mrq) | March 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -71.67% |
Return on Equity (ttm) | -169.78% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -55468000 USD |
Net Income Avi to Common (ttm) | -51702000 USD |
Diluted EPS (ttm) | -2.099 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 33.55M USD |
Total Cash Per Share (mrq) | 0.7 USD |
Total Debt (mrq) | 18.85M USD |
Total Debt/Equity (mrq) | 113.26 USD |
Current Ratio (mrq) | 1.652 |
Book Value Per Share (mrq) | 1.427 |
Cash Flow Statement
Operating Cash Flow (ttm) | -46624000 USD |
Levered Free Cash Flow (ttm) | -29384250 USD |
Profile of Entasis Therapeutics
Country | United States |
State | MA |
City | Waltham |
Address | 35 Gatehouse Drive |
ZIP | 02451 |
Phone | 781 810 0120 |
Website | https://www.entasistx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 51 |
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Q&A For Entasis Therapeutics Stock
What is a current ETTX stock price?
Entasis Therapeutics ETTX stock price today per share is 2.19 USD.
How to purchase Entasis Therapeutics stock?
You can buy ETTX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Entasis Therapeutics?
The stock symbol or ticker of Entasis Therapeutics is ETTX.
Which industry does the Entasis Therapeutics company belong to?
The Entasis Therapeutics industry is Biotechnology.
How many shares does Entasis Therapeutics have in circulation?
The max supply of Entasis Therapeutics shares is 0.
What is Entasis Therapeutics Price to Earnings Ratio (PE Ratio)?
Entasis Therapeutics PE Ratio is now.
What was Entasis Therapeutics earnings per share over the trailing 12 months (TTM)?
Entasis Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Entasis Therapeutics company belong to?
The Entasis Therapeutics sector is Healthcare.